“According to the research, the administration of the non-psychotropic component cannabidiol (C-B-D) significantly helps heal bone fractures.”
Hello David- I’ve been using liquid C-B-D oil through the Minnesota Medical Marijuana vendor, Leafline. Here’s the details concerning my use of C-B-D and the improvement I believe are attributed to its use with healing my lytic lesions and reducing the multiple myeloma bone pain.
In early November ’18, I had my 8th annual follow-up appointment at Mayo Clinic with my Hematology Oncologist who specializes in multiple myeloma. I had my annual full body CT scan to assess the condition of the hundreds of lytic lesions as a result of the destruction caused by the myeloma.
For about 2 years, as part of my treatment plan, I received infusions of Zometa that can help with replacing bone in these lytic lesions. Every year for the last 7 years, the lesions have shown no improvement.
In March, 2017, I relapsed and the myeloma aggressively grew in the marrow of my right femur, causing a fracture. The new treatment plan that includes immunotherapy, (darzelex/daratumumab) and radiation, has worked great.
That summer, I started using Medical Marijuana/C-B-D to help control the pain of the fracture and neuropathy, because I didn’t want to continue with the narcotics I was on. I’ve continued taking the MM/CBD for the past 17 mos, because of the additional benefits including the anti-inflammatory and bone rebuilding properties.
What I’ve been taking is their oral liquid products called “Tangerine” and “Cobalt”. The Tangerine is 2 mg T-H-C/ml w/trace amt of C-B-D. I take 4-5 ml at night. With my neuropathy pain, it helps me get to sleep, stay asleep and wake up w/o feeling groggy. It minimizes the pain, so I can fall asleep. As an oral prep, it takes about an hr for it to take effect. The Cobalt is 20 mg CBD/ml w/1mg THC/ml. I take 1 ml of Cobalt in the morning.
For the first time, the CT scan showed improvement to the lesions in some areas, particularly in the fractured femur as well as other places.
This is an excerpt from a scientific article showing a study of how C-B-D helps heal bone fractures & how the bones are even stronger than before: “According to the research, the administration of the non-psychotropic component cannabidiol (C-B-D) significantly helps heal bone fractures. The study, conducted on rats with mid-femoral fractures, found that C-B-D — even when isolated from tetrahydrocannabinol (T-H-C), the major psychoactive component of cannabis — markedly enhanced the healing process of the femora after just eight weeks”.
I hope this helps show, anecdotally at least, that there may be a benefit for myeloma.
Best regards & blessings, Sally
Dear Sally,
Thank you very much for your experiences. I agree that your experience is anecdotal but MMers freqently ask me about the application of C-B-D to myeloma so this helps.
If you or a loved one have been diagnosed with Multiple Myeloma, let me say this loud and clear:
It is critical that you become an active participant in your care. Learn everything you can.
I am alive today largely because I took the time to find out everything I could about Multiple Myeloma and sought out the full spectrum of evidence-based MM therapies both conventional (FDA approved) and non-conventional. C-B-D would definitely be considered non-conventional.
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
“A new study explores another promising new medical application for medical marijuana. According to the research, the administration of the non-psychotropic component significantly helps heal bone fractures…
According to the research, the administration of the non-psychotropic component cannabinoid cannabidiol (C-B-D) significantly helps heal bone fractures. The study, conducted on rats with mid-femoral fractures, found that C-B-D — even when isolated from tetrahydrocannabinol (T-H-C), the major psychoactive component of cannabis — markedly enhanced the healing process of the femora after just eight weeks…
“The clinical potential of cannabinoid-related compounds is simply undeniable at this point,” said Dr. Gabet. “While there is still a lot of work to be done to develop appropriate therapies, it is clear that it is possible to detach a clinical therapy objective from the psychoactivity of cannabis. C-B-D, the principal agent in our study, is primarily anti-inflammatory and has no psychoactivity…”
